Blue Cross Blue Shield of Michigan

A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Submit medical drug prior authorization requests online

As part of our efforts to make the prior authorization (PA) process more efficient, we're encouraging prescribers register and use our Web-based system when prescribing medical drugs for commercial members. This new application gives providers the ability to submit forms electronically and the ability to lookup the status of their medical drug PA request.

In-state Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Become a registered Availity user by clicking the following hyperlink, **availity.com/bcbsm**, and following the steps.

To request a drug prior authorization, please go to bcbsm.com and follow these easy steps:

Log into the Availity

- Navigate to **availity.com**, and enter your provided username and password
- Click the Payer Spaces drop down and select BCBSM BCN icon
- Scroll down the page and select the appropriate Novologix link for your member

Complete the Prior Authorization Request

- To login to Novologix, enter your User ID and Password
- Click the Authorizations drop down and select Create Authorization
- Enter in the members specific details and select the correct member on contract
- Complete the required fields and select the correct drug product in the Authorization Lines section
- Click Submit and complete the question to request prior authorization

Out-of-State Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Access the Electronic Provider Access (EPA) via local Blues Plan
- Download the Registration form for electronic access from the Medical Prior Authorization Review link
  AND
- Submit the Registration form with a completed Medication Authorization Request Form (MARF) via fax or mail
- For additional information or instructions, please refer to the e-Learning Training Modules in the Provider Secure Services page OR contact the Help Desk at 877-258-3932

Disclaimer: Access is only available to registered users. A valid individual NPI is required for registration.

Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form
Nucala® (mepolizumab) HCPCS CODE: J2182

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Nucala®. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	**Name**
ID Number	**Specialty**
D.O.B. ☐Male ☐Female	**Address**
Diagnosis	**City /State/Zip**
Drug Name	**Phone/Fax: P**: ( ) - **F**: ( ) -
Dose and Quantity	**NPI**
Directions	**Contact Person**
Date of Service(s)	**Contact Person Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

1. Is this request for: ☐ Initiation ☐ Continuation ***Date patient started therapy***: _____
2. How is this medication being administered? ☐ Self-administered ***(Please fax this completed form to BCBSM at (866) 601-4425)*** ☐ Health Care Professional administered (Continue to #3)
3. Please provide reason(s) why the patient needs to receive Nucala administered by a healthcare professional:
   - ☐ Patients or caregivers who are unable to perform subcutaneous injections with proper technique
   - ☐ Patient requires monthly medical support from the physician
   - ☐ Other: _____
4. Site of administration? ☐ Provider office/Home infusion ☐ Other: _____
   ☐ Hospital outpatient facility (go to #4) *Reason for Hospital Outpatient administration:* _____
5. Please specify location of administration if hospital outpatient infusion: _____
6. Please provide the NPI number for the place of administration: _____
7. **Initiation AND Continuation of therapy:**
   a. Will the patient be using Nucala in combination with other biologic agents (for example: Xolair®, Fasenra™ or Cinqair®) or targeted DMARD medications?
      ☐ yes ☐ no Comment: _____
   b. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis with Nucala? ☐ Yes ☐ No Comment: _____
   c. Please check the patient's diagnosis**:** ☐ Severe eosinophilic asthma (**EA, go to d and e**) ☐ Hypereosinophilic syndrome (**HES go to d then h to j**)
      ☐ Eosinophilic granulomatosis with polyangiitis (**EGPA, go to f and g**)
      ☐ Chronic rhinosinusitis with nasal polyps (**CRSwNP, go to k**)
      ☐ Other: _____
   d. **EA and HES:** What is the patient's blood eosinophil level at initiation of treatment, in cells/microliter? ☐ Blood eosinophils level: _____ Date: _____
   e. **EA:** Which treatment(s) did not adequately control the patient's severe eosinophilic asthma symptoms after a trial of at least 3 months?
      ☐ Systemic corticosteroid: _____ Date: *Start:* _____ *End:* _____
      ☐ High dose inhaled corticosteroids: _____ Date: *Start:* _____ *End:* _____
      ☐ Long acting beta2-agonist: _____ Date: *Start:* _____ *End:* _____
      ☐ Leukotriene receptor antagonist: _____ Date: *Start:* _____ *End:* _____
      ☐ Combination asthma inhaler with a HIGH dose corticosteroid and a long acting beta agonist: _____ Date: *Start:* _____ *End:* _____
      ☐ Combination asthma inhaler with a MEDIUM dose corticosteroid and a long acting beta agonist: _____ Date: *Start:* _____ *End:* _____
      ☐ Long acting muscarinic antagonist (LAMA): _____ Date: *Start:* _____ *End:* _____
      ☐ Other: _____ Date: *Start:* _____ *End:* _____
   f. **EPGA:** Does the patient currently have asthma or have a history of asthma? ☐ yes ☐ no Comment: _____
   g. **EPGA:** How was the patient diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA)?
      ☐ Histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation
      ☐ Neuropathy ☐ Pulmonary infiltrates ☐ Allergic rhinitis and nasal polyps ☐ Cardiomyopathy ☐ Glomerulonephritis
      ☐ Alveolar hemorrhage ☐ Palpable purpura ☐ Antineutrophil cytoplasmic antibody (ANCA) positivity ☐ Other: _____ ☐ None
   h. **HES:** How many hypereosinophilic syndrome (HES) flares has the patient had within the past 12 months (defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy)? _____
   i. **HES:** Has the patient been stable on hypereosinophilic syndrome (HES) therapy for at least 4 weeks? (for example: oral corticosteroids, immunosuppressive or cytotoxic therapy).
      ☐ Yes ☐ No Comment: _____
   j. **HES:** Does the patient have eosinophilia of unknown clinical significance, non-hematologic secondary HES (for example: drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), or FIP1L1-PDGFRα kinase-positive hypereosinophilic syndrome (HES)?
      ☐ Yes ☐ No Comment: _____
   k. **CRSwNP:** Has the patient tried and failed intranasal corticosteroids (for example: Flonase)? ☐ Yes ☐ No Comment: _____
8. **Continuation request:** (please answer above questions as well): **Nucala start date**: _____
   a. Have the patient's signs and symptoms improved with Nucala? ☐ Yes ☐ No, Comment: _____ ☐ Other:_____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date

Step 2: Checklist	☐ Form Completely Filled Out ☐ Attach Chart Notes	☐ Attach Diagnostic Tests
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320**

11/6/2015; 2/25/2016; 2/2/2018; 10/11/2018; 1/31/2020; 3/17/2020; 12/3/2021; 10/7/2021; 10/6/2022